The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics

Marco Valvano 1, Marco Magistroni 1, Antonio Mancusi 1, Debora D’Ascenzo 1, Salvatore Longo 1, Gianpiero Stefanelli 1, Filippo Vernia 1, Angelo Viscido 1, Stefano Necozione 2 and Giovanni Latella 1,*

1 Gastroenterology, Hepatology and Nutrition Division, Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy; magistroni.marco@gmail.com (M.M.); a.mancusi8@gmail.com (A.M.); debora.dascenzo97@gmail.com (D.D.); salvator.longo@gmail.com (S.L.); giastefanelli@gmail.com (G.S.); filippo.vernia1@gmail.com (F.V.); angelo.viscido@univaq.it (A.V.)
2 Epidemiology Unit, Department of Life, Health and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy; stefano.necozione@univaq.it
* Correspondence: giolatel@tin.it; Tel.: +39-0862-434735

Abstract: The main role of vitamin D is calcium homeostasis and bone metabolism, although its activity as an immuno-modulator and its anti-inflammatory effect is well-known. Low blood vitamin D levels are common among patients with inflammatory bowel disease (IBD). Whether low vitamin D levels could affect the disease activity or it is an effect of a worse condition of the disease is still unclear. This study aimed to investigate the role of blood vitamin D levels to identify the clinical, endoscopic, and histological activity in a cohort of patients with ulcerative colitis (UC) or Crohn’s disease (CD) on therapy with biological drugs. In this retrospective cohort study, 50 IBD patients (24 UC and 26 CD) that underwent colonoscopy from January 2017 to January 2020 with a concomitant serological evaluation of vitamin D were included. Patients with clinical, endoscopic, and histological activity and those who lost their clinical response to the biological drug had lower vitamin D levels compared to patients in remission or patients that did not change therapeutic regimens. A receiver operating characteristic (ROC) analysis and Youden’s Index were performed to assess the optimal vitamin D levels to identify patients with the active disease. The ROC analysis showed an area under the curve (AUC) of 0.709 (p = 0.005; confidence interval (CI): 0.564–0.829), 0.769 (p < 0.001; CI: 0.628–0.876), and 0.810 (p < 0.001; CI: 0.670–0.910) for the clinical, endoscopic, and histological outcomes, respectively. The optimal vitamin D cut-off was ≤25 ng/mL. The vitamin D level is an additional useful tool in the evaluation of IBD patients with good accuracy to predict their endoscopic and histological activity and clinical response to biologics.

Keywords: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; vitamin D; biological therapy

1. Introduction

Inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic relapsing diseases [1,2]. Typically, the IBD clinical course is characterized by the alternation of periods of remission and flare-ups [3]. Although the etiology of IBD is still unclear, it involves a complex interaction between the genetic, environmental, and microbial factors and the immune responses [4]. Several studies have shown that vitamin D contributes to maintenance gut epithelial barrier integrity against inflammatory and pathogenic stimuli, suggesting that vitamin D plays a protective role in the pathogenesis of IBD [5,6]. The main role of vitamin D is calcium homeostasis and bone metabolism, although several potential actions have been suggested in the last two decades [7]. In particular, vitamin D deficiency has been reported in several chronic diseases associated with increased inflammation and deregulation of the immune system, including IBD [8,9]. It is estimated that 13% and 10% of CD and UC
patients, respectively, have a calcium deficiency [10]. It is important to underline that the prevalence of osteopenia or osteoporosis is higher among IBD patients on corticosteroid therapy [11], although, among these patients, low vitamin D levels and bone disease were observed independently of glucocorticoid administration [10]. A systematic review including 14 observational studies assessed the prevalence of vitamin D deficiency. It was 31.6% in UC and 38.1% in CD [12].

Among IBD patients, whether low vitamin D levels could affect the disease activity or if it is a secondary effect of a worse condition of the disease is still unclear [13].

A recent meta-analysis showed that, among IBD patients, low vitamin D levels were linked with increased odds of disease activity (odds ratio (OR) 1.53, 95% confidence interval (CI) 1.32–1.77, $I^2 = 0\%$), mucosal inflammation (OR 1.25, 95% CI 1.06–1.47, $I^2 = 0\%$), low quality of life (QOL) scores (OR 1.30, 95% CI 1.06–1.60, $I^2 = 0\%$), and clinical relapse (OR 1.23, 95% CI 1.03–1.47, $I^2 = 0\%$) [14]. It is important to underline that the definition of low vitamin status is extremely variable among the studies included in this meta-analysis, ranging from 10 to 35 ng/mL [15,16]. The optimal cut-off of serum vitamin D levels for the evaluation of disease activity in IBD patients has not been defined. Therefore, the vitamin D level as a tool for the evaluation of disease activity in IBD patients is far from being adopted.

The aim of this study was to investigate the efficacy of blood vitamin D levels to identify clinical, endoscopic, and histological activity in a cohort of patients with UC or CD on therapy with biological drugs.

2. Materials and Methods

2.1. Study Population

This is a retrospective, single-center, cohort study including IBD patients followed at the Gastroenterology, Hepatology and Nutrition division of the University of L’Aquila (L’Aquila, Italy).

All patients gave written consent to the anonymous processing of their data. Ethics approval was issued by the Internal Review Board of the University of L’Aquila (Protocol number: 9029). All clinical investigations were conducted according to the principles laid down in the Declaration of Helsinki.

IBD patients on biological therapy that underwent colonoscopy from January 2017 to January 2020 with a concomitant serological evaluation of vitamin D (within two months and without therapeutic change) were included. The diagnoses of UC and CD were based on standard clinical, endoscopic, histological, and cross-sectional imaging criteria [17]. All CD patients (always at diagnosis but, also, during follow-up when clinically needed) underwent routine cross-sectional imaging techniques, such as transabdominal ultrasound, computed tomography, or magnetic resonance, to evaluate in a more precise and complete way the localization, extension, and activity of their intestinal lesions.

Demographic (gender and age) and clinical data (years from diagnosis, IBD-related medications, oral supplementation of vitamin D, and season for sample collection) were collected.

2.2. Outcomes

Our primary outcome was the assessment of the optimal vitamin D cut-off (25-OH-D concentration in the serum) to identify patients with the active disease.

A clinical flare-up was defined by a clinical score. Partial Mayo clinic scores (PMS) and the Harvey-Bradshaw Index (HBI) were adopted for UC and CD, respectively. PMS $\geq 2$ in UC and HBI $\geq 5$ in CD identified the clinical activity [18].

Each patient was categorized with a Mayo endoscopic score (MES) or a simple endoscopic score (SES-CD) for UC and CD, respectively, based on the overall appearance of the ileal and colonic mucosa. MES $\geq 2$ or SES-CD $\geq 3$ corresponded to endoscopic activity [18].

At least two biopsies were taken from the ileum and all colon segments (cecum, ascending colon, transverse colon, descending colon, and sigmoid colon) and rectum for
the pathological examination. The endoscopy biopsies were sectioned and stained with hematoxylin and eosin for pathological examination. The histological activity was defined by the presence of inflammatory cell infiltrate in at least one of the histological sections [19].

Loss of response (LOR) to biological therapy was defined as the reappearance of significant and quantifiable clinical signs, e.g., moderate–severe activity evaluated with a specific clinical score (PMS and HBI for UC and CD, respectively), steroid dependence or steroid-refractory disease, and the need to change the biological drug treatment [20,21].

2.3. Vitamin D Serum Concentration Assay

An automated chemiluminescence system was used to determine the vitamin D (25-OH-D) concentrations in the serum (LIAISON® 25 OH Vitamin D TOTAL Assay 310600—DiaSorin Inc., Stillwater, MN, USA).

2.4. Statistical Analysis

For all statistical analyses, SAS software (version 9.4, Copyright© 2021–2012 by SAS Institute Inc., Cary, NC, USA) and MedCalc software (version 19.6 MedCalc® Ltd., Ostend, Belgium) were used. Continuous variables were reported as means with standard deviations (±SD). An unpaired two-sample t-test was performed to compare the vitamin D levels among active and inactive patients for each group (clinical, histologic, and endoscopic).

A receiver operating characteristic (ROC) analysis and Youden’s Index were performed to assess the accuracy of the vitamin D level evaluations to identify patients with the active disease for each group (clinical, endoscopic, and histologic activities) and the optimal vitamin D cut-off.

A McNemar test was performed to compare patients with endoscopic or histologic activity and identify those with the optimal vitamin D cut-off and patients with clinical activity.

A logistic regression test was used to evaluate the association, expressed as the odds ratio (OR), between vitamin D levels lower than the optimal cut-off and disease activity.

3. Results

Fifty IBD patients in biological therapy (24 UC and 26 CD) who underwent a colonoscopy from January 2017 to January 2020 in our unit, with a concomitant serological evaluation of vitamin D, were included in our analysis. All patients included in the study were Italian.

The blood samples for the vitamin D assessment were collected within two months before or after the colonoscopy with biopsies.

Overall, 17/50 (34%) patients presented clinical activity, 27/50 (54%) and 31/47 (65.9%) patients showed endoscopic and histological activity, respectively. Among the patients in clinical remission, 13/33 (39.4%) and 16/31 (51.6%) showed endoscopic and histological activity, respectively. Finally, 6/50 (12%) lost their response to therapy with biological drugs.

The baseline characteristics are shown in Table 1.

Patients with clinical, endoscopic, and histological activities had lower vitamin D levels compared to patients in remission (Figure 1).

3.1. ROC Analysis and Optimal Cut-Off

The ROC analysis and Youden’s Index were performed to assess the optimal vitamin D levels to identify patients with the active disease. The ROC analysis showed an area under the curve (AUC) of 0.709 ($p = 0.005$; CI: 0.564–0.829), 0.769 ($p < 0.001$; CI: 0.628–0.876), and 0.810 ($p < 0.001$; CI: 0.670–0.910) for the clinical, endoscopic, and histological outcomes, respectively (Figure 2).
| Table 1. Baseline demographic and clinical characteristics. |
|-----------------------------------------------------------|
|                                                          |
|                                                          |
| | Clinical Evaluation (n = 50)                             | Endoscopic Evaluation (n = 50) | Histologic Evaluation (n = 47) |
|                                                          |
| | Active (17)     | Inactive (33)               | Active (27)      | Inactive (23)               | Active (31)      | Inactive (16)               |
|-----------|------------------|----------------------------|------------------|-----------------------------|------------------|-----------------------------|
| Male/female | 10/7             | 16/17                     | 16/11            | 10/13                       | 18/13            | 8/8                          |
| Age        | 52 (22–76)       | 51.5 (21–76)              | 51.5 (21–65)     | 52.5 (28–76)                | 52 (21–65)       | 51.5 (28–76)                |
| Years from diagnosis | 12.5 (1–28) | 13 (1–36)               | 12.5 (1–33)      | 13 (1–36)                   | 13.5 (12–36)     | 12.5 (1–34)                |
| Crohn’s Disease (CD) | 7 (41%)     | 19 (58%)                  | 14 (52%)         | 12 (52%)                    | 15 (48%)         | 9 (56%)                     |
| CD localization |                     |                             |                  |                             |                  |                             |
| Ileal       | 1 (14%)         | 9 (47%)                   | 4 (29%)          | 6 (50%)                     | 5 (33%)          | 5 (55%)                     |
| Colonic     | 1 (14%)         | 0 (0%)                    | 1 (7%)           | 0 (0%)                      | 1 (7%)           | 0 (0%)                      |
| Ileocolonic | 5 (72%)         | 10 (53%)                  | 9 (64%)          | 6 (50%)                     | 9 (60%)          | 4 (45%)                     |
| Ulcerative Colitis (UC) | 10 (59%) | 14 (42%)      | 13 (48%)         | 11 (48%)                    | 16 (52%)         | 7 (44%)                     |
| UC localization |                     |                             |                  |                             |                  |                             |
| Proctitis   | 0 (0%)          | 0 (0%)                    | 0 (0%)           | 0 (0%)                      | 0 (0%)           | 0 (0%)                      |
| Left sided colitis | 7 (70%)     | 5 (36%)                   | 8 (62%)          | 4 (36%)                     | 9 (56%)          | 3 (43%)                     |
| Pancolitis  | 3 (30%)         | 9 (64%)                   | 5 (38%)          | 7 (64%)                     | 7 (44%)          | 4 (67%)                     |
| Intestinal surgery |                     |                             |                  |                             |                  |                             |
| CD          | 4 (57%)         | 11 (58%)                  | 7 (50%)          | 8 (67%)                     | 9 (60%)          | 5 (56%)                     |
| UC          | 0 (0%)          | 0 (0%)                    | 0 (0%)           | 0 (0%)                      | 0 (0%)           | 0 (0%)                      |
| Therapy     |                     |                             |                  |                             |                  |                             |
| Infliximab  | 4 (23%)         | 12 (36%)                  | 8 (30%)          | 8 (35%)                     | 9 (29%)          | 6 (37%)                     |
| Adalimumab  | 3 (18%)         | 7 (21%)                   | 6 (22%)          | 4 (17%)                     | 6 (19%)          | 2 (13%)                     |
| Vedolizumab | 5 (29%)         | 14 (43%)                  | 8 (30%)          | 11 (47%)                    | 11 (36%)         | 8 (50%)                     |
| Golimumab  | 2 (12%)         | 0 (0%)                    | 2 (7%)           | 0 (0%)                      | 2 (6%)           | 0 (0%)                      |
| Ustekinumab | 3 (18%)         | 0 (0%)                    | 3 (11%)          | 0 (0%)                      | 3 (10%)          | 0 (0%)                      |
| Oral supplemenation |                     |                             |                  |                             |                  |                             |
| Vitamin D  |                     |                             |                  |                             |                  |                             |
| Yes        | 7 (41%)         | 17 (52%)                  | 11 (41%)         | 13 (57%)                    | 14 (45%)         | 8 (50%)                     |
| No         | 8 (47%)         | 15 (45%)                  | 14 (52%)         | 9 (39%)                     | 15 (48%)         | 7 (44%)                     |
| n.a.       | 2 (12%)         | 1 (3%)                    | 2 (7%)           | 1 (4%)                      | 2 (7%)           | 1 (6%)                      |
| Season of sample collection |                     |                             |                  |                             |                  |                             |
| Autumn     | 4 (24%)         | 3 (9%)                    | 4 (15%)          | 3 (14%)                     | 5 (16%)          | 2 (13%)                     |
| Winter     | 6 (35%)         | 10 (30%)                  | 9 (33%)          | 7 (30%)                     | 8 (26%)          | 5 (31%)                     |
| Spring     | 3 (17%)         | 9 (27%)                   | 6 (22%)          | 6 (26%)                     | 9 (29%)          | 3 (19%)                     |
| Summer     | 4 (24%)         | 11 (33%)                  | 8 (30%)          | 7 (30%)                     | 9 (29%)          | 6 (37%)                     |

*n (Median; range); n (%) n.a.: not applicable. CD: Chron’s disease. UC: ulcerative colitis.
Figure 1. Mean levels (±SD) of vitamin D (ng/mL) in patients with the active and inactive disease. (*) $p = 0.0062$, (**) $p = 0.002$, and (***) $p = 0.0013$.

Figure 2. The receiver operating characteristic (ROC) analysis to set the optimal cut-off value of vitamin D to assess the (a) clinical activity, (b) endoscopic activity, and (c) histologic activity. AUC: area under the curve.
For the AUC with better performance (histologic group; AUC 0.810), the Youden’s Index assessed the optimal vitamin D cut-off at $\leq 25$ ng/mL. It showed the best accuracy and identified 53.8% (7/13) and 87.5% (14/16) of the patients as having endoscopic and histologic activity, although these patients were in clinical remission (McNemar’s test: $p = 0.0184$) (Figure 3). Furthermore, vitamin D $\leq 25$ ng/mL identified 100% (6/6) of the patients who lost their response to biological drugs (6/50).

**Figure 3.** Vitamin D levels in patients in clinical remission and endoscopic or histologic activity.

### 3.2. Vitamin D under the Set Threshold and Odds Ratio of Disease Activity

A logistic regression test was used to evaluate the association between vitamin D levels lower than the optimal cut-off and disease activity. The odds ratio (OR) was 6.44 (CI: 1.7–26.5) for clinical activity, OR 11.33 (CI: 2.7–47.9) for endoscopic activity, and OR 20.12 (CI: 3.7–108.6) for histologic activity.

### 4. Discussion

Despite the evidence of the associations between disease activity and low vitamin D levels [14], its usefulness in the assessment of IBD patients is debated [22–24]. A plethora of biomarkers with various accuracies have been proposed for the evaluation of the disease’s activity in IBD patients [25,26]. However, the usefulness of serum vitamin D levels in the assessment of disease activity in an IBD population has not been carried out. Furthermore, the optimum vitamin D cut-off has not yet been established to assess the real risk of clinical relapse [23].

Moreover, if low vitamin D levels could affect the disease activity or if it is a secondary effect of a worse condition of the disease is still unclear [13]. It was reported that adult IBD patients had higher odds of vitamin D deficiency when compared to healthy controls (OR = 1.81; 95% CI: 1.37, 2.40; $I^2 = 1\%$; $p < 0.0001$) [12].

In CD, the ileal localization of lesions or surgical resection of the distal ileum may lead to bile acid diarrhea and contribute, with the use of bile acid sequestrants, to the vitamin D deficiency. However, in our cohort of CD patients, the rate of both ileal and/or ileocolic involvement of the lesions and ileal surgery was not significantly different between patients with the active disease and patients with the inactive disease (Table 1). Moreover, the CD patients with an inactive disease more often showed an ileal localization of the disease.
Therefore, the disease activity appears to play an important role in inducing a vitamin D deficiency. An inverse correlation between CD clinical activity and the blood levels of vitamin D were found ($r = -0.42276; p = 0.0314$).

A randomized clinical trial showed that the relapse rate among patients treated with a supplementation of vitamin D was lower (6/46 or 13%) compared to a placebo (14/48 or 29%), and the survival analysis showed higher relapse-free time in the group of patients treated with vitamin D supplementation (hazard ratio (HR), 0.42; CI 0.16–1.10) ($p = 0.06$) [27].

A single-center observational study evaluated if the vitamin D status before antitumor necrosis factor-α (anti-TNFα) therapy influenced the durability of treatment in IBD patients. This study showed an inverse association with the duration of anti-TNFα treatment and vitamin D levels, with a more pronounced effect on patients with CD. Patients with insufficient vitamin D showed an early cessation of anti-TNFα therapy due to a loss of response (HR, 3.49; 95% CI, 1.34–9.09) [28].

In addition, a five-year observational study including 965 IBD patients showed that patients with a low mean vitamin D level required more steroids, biologics, emergency department visits, hospital admissions, and surgery compared with subjects with normal mean vitamin D levels ($p < 0.05$) [29].

Several evidences suggested a potential role of vitamin D in the pathophysiology of IBD, although further studies are warranted to clarify this issue.

The primary outcome of our study was to assess the optimal vitamin D levels to identify the endoscopic or histologic active disease and to determine the usefulness of serum vitamin D levels in IBD patients with both the clinical active and inactive disease.

The ROC analysis has shown good accuracy of the vitamin D serum level, under a set threshold, to identify patients with endoscopic or histological activity. In particular, using as the optimal cut-off $\leq 25$ ng/mL, the sensitivity and specificity were 74–88% and 74–70% in the assessment of histologic and endoscopic activity, respectively. The AUC was 0.810 ($p = 0.001$; CI: 0.670–0.910) and 0.769 ($p < 0.001$; CI: 0.628–0.876) for histologic and endoscopic activity evaluations, respectively.

Our results showed lower vitamin D levels in patients with the active disease (expressed as clinical, endoscopic, or histologic activity). Moreover, adopting the cut-off established with the ROC analysis and the Youden’s index, insufficient vitamin D levels were linked with increased odds of disease activity.

Furthermore, among patients who stopped treatment due to a loss of response (6/50), vitamin D levels $\leq 25$ ng/mL were observed in all cases.

Our study had some limitations. In particular, the small sample size was the main limitation, and larger studies are needed to confirm our results. Second, the observational design made it difficult to assess a cause-effect ratio between the low vitamin D status and disease activity. On the other hand, the use of a rigid score for the evaluation of our outcome made our results reliable.

In conclusion, taking into account the widespread use of vitamin D estimation for a global assessment in IBD patients, its low cost, and the accuracy of its evaluation for the assessment of the disease activity, we suggested that vitamin D may be used to predict endoscopic and histologic activity or a loss of response of biological therapy in IBD patients. The optimal cut-off was identified at $\leq 25$ ng/mL.

The vitamin D level is an additional useful tool in the evaluation of IBD patients, with sufficient accuracy to predict the endoscopic and histological activity.

**Author Contributions:** Conceptualization and study design, G.L. and M.V.; software and formal analysis, S.N.; data collection, M.M., A.M., and D.D.; critical revision of the manuscript and data curation, F.V., S.L., and G.S.; writing—original draft preparation, M.V.; writing—review and editing, G.L. and A.V.; and supervision, G.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the University of L’Aquila, L’Aquila, Italy (Protocol number: 9029).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: No supporting data is available.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ordás, I.; Eckmann, L.; Talamini, M.; Baumgart, D.C.; Sandborn, W.J. Ulcerative colitis. *Lancet* 2012, 380, 1606–1619. [CrossRef]
2. Baumgart, D.C.; Sandborn, W.J. Crohn’s disease. *Lancet* 2012, 380, 1590–1605. [CrossRef]
3. Magro, F.; Gionchetti, P.; Eliakim, R.; Ardizzone, S.; Armuzzi, A.; Barreiro-de Acosta, M.; Burisch, J.; Geese, K.B.; Hart, A.L.; Hindryckx, P.; et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. *J. Crohn’s Colitis* 2017, 11, 649–670. [CrossRef]
4. Zhang, Y.Z.; Li, Y.Y. Inflammatory bowel disease: Pathogenesis. *World J. Gastroenterol.* 2014, 20, 91–99. [CrossRef]
5. Nielsen, O.H.; Rejmark, L.; Moss, A.C. Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. *J. Crohn’s Colitis* 2016, 12, 742–752. [CrossRef] [PubMed]
6. Cantorna, M.T.; Snyder, L.; Arora, J. Vitamin A and vitamin D regulate the microbial complexity, barrier function, and the mucosal immune responses to ensure intestinal homeostasis. *Crit. Rev. Biochem. Mol. Biol.* 2019, 54, 184–192. [CrossRef] [PubMed]
7. Dusso, A.S.; Brown, A.J.; Slatopolsky, E. Vitamin D. *Am. J. Physiol. Ren. Physiol.* 2005, 289, 8–28. [CrossRef] [PubMed]
8. Grishan, F.K.; Kiela, P.R. Vitamins and minerals in IBD. *Gastroenterol. Clin. N. Am.* 2018, 176, 139–148. [CrossRef]
9. Sassi, F.; Tamone, C.; D’Amelio, P. Vitamin D: Nutrient, Hormone, and Immunomodulator. *Nutrients* 2018, 10, 1656. [CrossRef]
10. Massironi, S.; Rossi, R.E.; Cavalcoli, F.A.; Della Valle, S.; Fraquelli, M.; Conte, D. Nutritional deficiencies in inflammatory bowel disease: Therapeutic approaches. *Clin. Nutr.* 2013, 32, 904–910. [CrossRef]
11. Bjarnason, I.; MacPherson, A.; Mackintosh, C.; Buxton-Thomas, M.; Forgacs, I.; Moniz, C. Reduced bone density in patients with inflammatory bowel disease. *Gut* 1997, 40, 228–233. [CrossRef] [PubMed]
12. Del Pinto, R.; Pietropaoli, D.; Chandar, A.K.; Ferri, C.; Cominelli, F. Association between Inflammatory Bowel Disease and Vitamin D Deficiency. *Inflamm. Bowel Dis.* 2015, 21, 2708–2717. [CrossRef] [PubMed]
13. Ananthakrishnan, A.N.; Khalili, H.; Higuchi, L.M.; Bao, Y.; Korzenik, J.R.; Giovannucci, E.L.; Richter, J.M.; Fuchs, C.S.; Chan, A.T. Higher Predicted Vitamin D Status is Associated with Reduced Risk of Crohn’s Disease. *Gastroenterology* 2012, 142, 482–489. [CrossRef] [PubMed]
14. Gubatan, J.; Chou, N.D.; Nielsen, O.H.; Moss, A.C. Systematic review with meta-analysis: Association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease. *Aliment. Pharmacol. Ther.* 2019, 50, 1146–1158. [CrossRef]
15. Gubatan, J.; Mitsubishi, S.; Zenlea, T.; Rosenberg, L.; Robson, S.; Moss, A.C. Low Serum Vitamin D during Remission Increases Risk of Clinical Relapse in Patients with Ulcerative Colitis. *Clin. Gastroenterol. Hepatol.* 2017, 15, 240–246.e1. [CrossRef]
16. Hassan, V.; Hassan, S.; Seyed-Javad, P.; Ahmad, K.; Asieh, H.; Maryam, S.; Farid, F.; Siavash, A. Association between Serum 25 (OH) Vitamin D Concentrations and Inflammatory Bowel Diseases (IBDs) Activity. *Med. J. Malays.* 2013, 68, 34–38.
17. Maeser, C.; Sturm, A.; Vavricka, S.R.; Kucharzik, T.; Fiorino, G.; Annese, V.; Calabrese, E.; Baumgart, D.C.; Bettenworth, D.; Borralho Nunes, P.; et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *J. Crohn’s Colitis* 2019, 13, 144–164. [CrossRef]
18. Sturm, A.; Maeser, C.; Calabrese, E.; Annese, V.; Fiorino, G.; Kucharzik, T.; Vavricka, S.R.; Verstockt, B.; Van Rheenen, P.; Tolan, D.; et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. *J. Crohn’s Colitis* 2019, 13, 273–284. [CrossRef]
19. Bryant, R.V.; Winer, S.; Spl, T.; Riddell, R.H. Systematic review: Histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. *J. Crohn’s Colitis* 2014, 8, 1582–1597. [CrossRef]
20. Allez, M.; Karmiris, K.; Louis, E.; Van Assche, G.; Ben-Horin, S.; Klein, A.; Van Der Woude, J.; Baert, F.; Eliakim, R.; Katsanos, K.; et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. *J. Crohn’s Colitis* 2014, 4, 355–366. [CrossRef]
21. Schnitzler, F.; Fiddler, H.; Ferrante, M.; Noman, M.; Arijs, I.; Van Assche, G.; Hoffman, I.; Van Steen, K.; Vermeire, S.; Rutgeerts, P. Long-term outcome of treatment with infiximab in 614 patients with Crohn’s disease: Results from a single-centre cohort. *Gut* 2009, 58, 492–500. [CrossRef] [PubMed]
22. Mouli, V.P.; Ananthakrishnan, A.N. Review article: Vitamin D and inflammatory bowel diseases. *Aliment. Pharmacol. Ther.* 2014, 39, 125–136. [CrossRef] [PubMed]
23. López-Muñoz, P.; Beltrán, B.; Sáez-González, E.; Alba, A.; Nos, P.; Ibórta, M. Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients. *Nutrients* 2019, 11, 1059. [CrossRef]
24. Gubatan, J.; Moss, A.C. Vitamin D in inflammatory bowel disease: More than just a supplement. *Curr. Opin. Gastroenterol.* 2018, 34, 217–225. [CrossRef] [PubMed]
25. Vernia, F.; Di Ruscio, M.; Stefanelli, G.; Viscido, A.; Frieri, G.; Latella, G. Is fecal calprotectin an accurate marker in the management of Crohn’s disease? *J. Gastroenterol. Hepatol.* 2020, 35, 390–400. [CrossRef] [PubMed]
26. Di Ruscio, M.; Vernia, F.; Ciccone, A.; Frieri, G.; Latella, G. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin? *Inflamm. Bowel Dis.* 2017, 24, 78–92. [CrossRef] [PubMed]
27. Jørgensen, S.P.; Agnholt, J.; Glerup, H.; Lyhne, S.; Villadsen, G.E.; Hvas, C.L.; Bartels, L.E.; Kelsen, J.; Christensen, L.A.; Dahlerup, J.F. Clinical trial: Vitamin D3 treatment in Crohn’s disease—A randomized double-blind placebo-controlled study. *Aliment. Pharmacol. Ther.* 2010, 32, 377–383. [CrossRef]
28. Zator, Z.A.; Cantu, S.M.; Konijeti, G.G.; Nguyen, D.D.; Sauk, J.; Yajnik, V.; Ananthakrishnan, A.N. Pretreatment 25-Hydroxyvitamin D Levels and Durability of Anti–Tumor Necrosis Factor–α Therapy in Inflammatory Bowel Diseases. *J. Parenter. Enter. Nutr.* 2014, 38, 385–391. [CrossRef]
29. Kabbani, T.A.; Koutroubakis, I.E.; Schoen, R.E.; Ramos-Rivers, C.; Shah, N.; Swoger, J.; Regueiro, M.; Barrie, A.; Schwartz, M.; Hashash, J.G.; et al. Association of Vitamin D Level with Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. *Am. J. Gastroenterol.* 2016, 111, 712–719. [CrossRef]